Introduction
Acute myocardial infarction (AMI), a prominent contributor to morbidity and mortality within the realm of cardiovascular diseases (CVD), holds substantial global significance. In the United States (US), the overall prevalence of AMI among adults aged 20 years and above is estimated to stand at 3.2%, based on NHANES data spanning from 2017 to 2020. In the year 2020 alone, AMI was responsible for approximately 109,199 fatalities in the US.1 The World Banks projections indicate an escalating number of AMI cases in China, with estimates reaching 23 million by the year 2030.2 Despite the noteworthy decline in mortality rates attributed to AMI due to the advancements in PCI, the prognosis remains unfavorable. Hence, it holds paramount importance to identify risk factors that can serve as prognostic indicators for patients with AMI, enabling timely intervention.
AMI primarily arises from coronary atherosclerosis, wherein inflammation and abnormal lipid metabolism play pivotal roles in its pathogenesis.36 Previous investigations have indicated a strong correlation between the abundance of neutrophils, monocytes, high-density lipoprotein cholesterol (HDL-C), and the occurrence of atherosclerosis and MACE.711 Moreover, HDL-C exerts a protective effect against atherosclerosis and MACE by modulating the function of neutrophils and monocytes, inhibiting their activation. Presently, several studies propose that a combination of inflammatory and lipid markers may offer a more comprehensive reflection of CVD prognosis compared to a solitary lipid marker. Notably, MHR and NHR, as novel composite indices, demonstrate predictive value for CAD and MACE.1214 While the correlation between NHR and STEMI has been explored to a limited extent, no relevant research has been conducted on the prognostic capacity of NHR for MACE following PCI or the degree of coronary artery stenosis in hospitalized STEMI patients, rendering this a relatively novel research avenue.
This study aims to compare the predictive value of NHR and MHR, two indices incorporating inflammation and lipids, in relation to the occurrence of MACE in hospitalized patients with AMI after PCI. Additionally, this study evaluates the predictive value of NHR for extent of coronary artery stenosis assessed by the GS. By doing so, it seeks to further elucidate the significance of NHR and MHR in relation to MACE occurrence in hospitalized patients with AMI after PCI. The results demonstrate that NHR exhibits superior predictive value compared to MHR for MACE. Furthermore, in terms of predicting the degree of coronary artery stenosis as assessed by the GS, NHR shows certain predictive value, while MHR is not a relevant predictor.
This retrospective study was conducted at a single center, specifically the Third Affiliated Hospital of Anhui Medical University. The study involved the collection of data from 486 patients diagnosed with STEMI between the years 2020 and 2023 (Figure 1). The inclusion criteria for the study were as follows:1. All patients diagnosed with AMI according to the 2019 Chinese Society of Cardiology guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction. 2. All patients signed an informed consent form and underwent coronary angiography (CAG). 3.Primary PCI was performed to revascularize the culprit vessels, and successful revascularization treatment was anticipated. The following were the exclusion criteria for patient selection: 1. Refuse to undergo CAG or other reasons, the extent of coronary artery lesions is not clear. 2. Patients with severe abnormalities in liver and kidney function, autoimmune diseases, hereditary familial hypercholesterolemia, malignant tumors, or recent severe infections. 3.Patients who had previously undergone PCI or coronary artery bypass grafting for AMI. 4.Cases where primary PCI failed to revascularize the culprit vessels. Following the application of the aforementioned inclusion and exclusion criteria, a total of 486 patients were ultimately enrolled in the study. Among them, the subjects were categorized into two groups: the MACE group (n=148, 30.45%), comprising patients who experienced MACE during hospitalization after PCI, and the Non-MACE group (n=338, 69.55%), comprising patients who did not experience MACE. The study protocol and informed consent procedures were approved by the Ethics Committee of the Third Affiliated Hospital of Anhui Medical University.
Figure 1 Flow chart of the study selection.
Abbreviations: MACE, Major adverse cardiovascular event; STEMI St-segment elevation acute myocardial infarction; CAG, coronary arteriography.
The study collected various data from the medical record system, including demographic information of patients (such as gender, age, history of hypertension, diabetes, and stroke), vital sign data (systolic blood pressure, diastolic blood pressure, and heart rate), laboratory data within 24 hours of admission (neutrophils, monocytes, lymphocytes, serum creatinine (sCr), blood urea nitrogen (BUN), uric acid (UA), platelets, albumin (ALB), HDL-C, low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) and fasting plasma glucose (FPG), echocardiography data (left ventricular ejection fraction [LVEF] and left ventricular fractional shortening [LVFS]), as well as data related to CAG (including GS, which reflects the degree of stenosis in coronary artery).
In this study, the following definitions were used:
MACE encompassed all-cause mortality, new stroke after AMI, recurrent myocardial infarction, malignant arrhythmia, and new-onset heart failure after AMI.
NHR was defined as the ratio of neutrophils to HDL-C, while MHR represented the ratio of monocytes to HDL-C.
The patients were divided into three groups based on their GS: the low GS group (GS < 44), the medium GS group (GS 44 and 80), and the high GS group (GS > 80).
The statistical analysis in this study was performed using IBM SPSS Statistics 26.0 (IBM, New York, NY, USA) and R version 4.2.2 (R Foundation for Statistical Computing, University of Science and Technology of China). Continuous variables were presented as mean standard deviation or median (interquartile range). To compare data between two groups, the T test or MannWhitney U-test was employed depending on the normality of the data. The non-normally distributed GS data among the three groups were analyzed using the KruskalWallis H-test. Categorical variables were presented as numbers and percentages, and the Chi-square test or Fishers exact test was used for statistical analysis. Univariate and multivariate logistic regression analyses were conducted to evaluate the risk factors for MACE after PCI and severe coronary artery stenosis during hospitalization. ROC curves were generated to determine the cut-off values and predictive power of NHR, MHR, and LDL-C/HDL-C. Spearman correlation analysis was performed to assess the correlation between NHR, MHR, LDL-C/HDL-C, and the GS. Except for the LR backward stepwise multivariate logistic regression analysis (where variables with P < 0.05 were included, and variables with P > 0.10 were removed), all statistical tests were two-tailed, and a significance level of P < 0.05 was considered statistically significant.
In the comparison of baseline characteristics between the in-hospital MACE group and the non-MACE group, the following findings were observed: In the MACE group, the age, neutrophil count, monocyte count, sCr, BUN, UA, HDL-C, FPG, Killip class 24, GS, MHR, NHR, and LDL-C/HDL-C were significantly higher compared to the Non-MACE group (P < 0.05) (Table 1) (Figure 2A-D). Systolic blood pressure, diastolic blood pressure, and TG were significantly lower in the MACE group compared to the Non-MACE group (P < 0.05). No significant differences were observed in other indicators between the two groups (P > 0.05) (Table 1).
Table 1 Baseline Demographic and Clinical Characteristics of the Study Population According to in-Hospital Major Adverse Cardiovascular Events
Figure 2 (A) Comparison of NHR according to in-hospital major adverse cardiovascular events. (B) Comparison of MHR according to in-hospital major adverse cardiovascular events. (C) Comparison of LDL-C/HDL- according to in-hospital major adverse cardiovascular events. (D) Comparison of Gensini score according to in-hospital major adverse cardiovascular events. ***P<0.001.
Abbreviations: NHR, Neutrophil to HDL-C ratio; MHR, Monocyte to HDL-C ratio; HDL-C, High-density lipoprotein cholesterol; LDL-C, Low-density lipoprotein cholesterol; MACE, major adverse cardiovascular events.
Based on the GS, the patients were categorized into three groups: high GS group (GS > 80), medium GS group (44 GS 80), and low GS group (GS < 44). The following observations were made: Significant differences were found in age, history of hypertension, heart rate, neutrophils, monocytes, LDL-C, TC, TG, MHR, NHR, and LDL-C/HDL-C (P < 0.05). No significant differences were observed in other indicators (P > 0.05) (Table 2).
Table 2 Comparison of Demographic, Clinical, and Laboratory Characteristics Among the Low Gensini Score Tertile (Group 1: GS<44), Medium Gensini Score Tertile (Group 2: 44GS80), and High Gensini Score Tertile (Group 3: GS>80)
After grouping the medium GS group and low GS group as the non-high GS group, a comparison was made between the non-high GS group and the high GS group. The following findings were noted: The high GS group exhibited significantly higher heart rate, neutrophil count, monocyte count, UA, BUN, TG, TC, LDL-C, FPG, NHR, MHR, and LDL-C/HDL-C compared to the non-high GS group (P < 0.05) (Table 3) (Figure 3A-C). The incidence of Anterior MI and Killip class 24 was significantly higher in the high GS group than in the non-high GS group (Table 3). No significant differences were observed in other indicators (P > 0.05) (Table 3).
Table 3 Comparison of Demographic, Clinical, and Laboratory Characteristics Between the High Gensini Score Group (GS >80 Points) and Non-High Gensini Score Group (GS80 Points)
Figure 3 (A) Comparison of NHR according to Gensini score>80. (B) Comparison of MHR according to Gensini score>80. (C) Comparison of LDL-C/HDL-C according to Gensini score>80. ***P<0.001.
Abbreviations: NHR, Neutrophil to HDL-C ratio; MHR, Monocyte to HDL-C ratio; HDL-C, High-density lipoprotein cholesterol; LDL-C, Low-density lipoprotein cholesterol.
In the comparison between the MACE group and the Non-MACE group, the following results were observed: The GS of the MACE group was significantly higher compared to the Non-MACE group (P < 0.05). The LVEF and LVFS of the MACE group were significantly lower than those of the Non-MACE group (P < 0.05) (Table 1) (Figure 2D).
In the comparison between the non-high GS group and the high GS group, the following findings were noted: There was no significant difference in LVEF and LVFS between the two groups (P > 0.05) (Table 3).
Univariate logistic regression analysis was conducted to assess the risk factors of MACE during hospitalization, considering various factors including age, systolic blood pressure, diastolic blood pressure, BUN, sCr, UA, FPG, NHR, MHR, LDL-C/HDL-C, GS, LVEF, and LVFS. The results revealed the following: Age, sCr, BUN, UA, GS, MHR, NHR, LDL/HDL, Killip 24, and LVEF were identified as risk factors for MACE in AMI patients during hospitalization after PCI (P < 0.05). Systolic blood pressure, diastolic blood pressure, and TG were identified as protective factors for MACE in STEMI patients during hospitalization after PCI, while FPG did not show statistical significance (P > 0.05) (Table 4).
Table 4 Univariate Logistic Regression Analysis and Multivariate Logistic Regression Analysis of Selected Variables on in-Hospital Major Adverse Cardiovascular Events
The significant variables from the univariate regression were included in the LR backward stepwise multivariate regression analysis. After adjusting for factors such as BUN and UA, the multivariate logistic regression analysis revealed that sCr, MHR, NHR, LDL-C/HDL-C, Killip 24, and diastolic blood pressure remained as independent risk factors for MACE after primary PCI in patients with STEMI during hospitalization (MHR OR: 2.347, 95% CI: 1.0825.089, P=0.031) (NHR OR: 1.092, 95% CI: 1.0251.165, P=0.004) (P < 0.05) (Table 4). Additionally, systolic blood pressure and LVEF were identified as protective factors (P < 0.05) (Table 4). To demonstrate the association of NHR with high GS group, all patients were divided into four groups according to the quartile values of NHR (Q1: NHR 5.29, Q2: NHR 5.297.48, Q3: NHR 7.4810.49, Q4: NHR > 10.49). The OR value of MACE in the highest quartile compared with the lowest quartile was 6.17 (95% CI: 3.3411.39, p < 0.001) (Table 5). After adjusting for gender, age, Killip Class 24, systolic pressure, diastolic blood pressure, heart rate, smoking, stroke, diabetes, hypertension, Gensini score, platelet counts, FPG, BUN, sCr, UC, ALB, TG, LDL-C, LVEF and LVFS, the risk of MACE remained significantly higher in the highest quartile than in the lowest quartile (OR: 8.15, 95% CI: 3.6318.29, p <0.001) (Table 5). Finally, after further adjusting for the above confounding factors, the results of a trend analysis suggest that the trend of an increasing probability of MACE occurrence with rising NHR holds statistical significance (OR: 1.79, 95% CI: 1.402.30, P < 0.001) (Table 5).
Table 5 Multivariate Logistic Analysis to Determine Associations Between NHR Subgroup Levels and MACE
Univariate logistic regression analyses were performed for the high GS score group (GS > 80). The results indicated that heart rate, uric acid, TG, NHR, MHR, LDL-C/HDL-C, Killip 24, and Anterior MI were risk factors for complex coronary artery lesions. The significant indicators from the univariate regression were included in the backward LR backward multivariate regression analysis. After adjusting for factors such as heart rate, MHR and UA, LDL-C/HDL-C, NHR, Killp2-4 and Anterior MI were identified as independent risk factors for complex coronary artery lesions (NHR: OR:1.103, 95% CI:1.0471.162, P<0.001) (P < 0.05) (Table 6).
Table 6 Univariate and Multivariate Logistic Regression Analysis of Selected Variables on a High Gensini Score (>80 Points)
To demonstrate the association of NHR with high GS, all patients were divided into four groups according to the quartile values of NHR (Q1: NHR 5.29, Q2: NHR 5.297.48, Q3: NHR 7.4810.49, Q4: NHR > 10.49, Table 4). The OR value of high GS in the highest quartile compared with the lowest quartile was 4.15 (95% CI: 2.247.69, P < 0.001) (Table 7). After adjusting for gender, age, Killip Class 24, systolic pressure, diastolic blood pressure, heart rate, smoking, stroke, diabetes, hypertension, platelet counts, FPG, BUN, sCr, UC, ALB, TG, HDL-C, LDL-C, LVEF and LVFS, the risk of high GS remained significantly higher in the highest quartile than in the lowest quartile (OR:3.29, 95% CI: 1.527.13, p =0.0025) (Table 7). After further adjusting for the above confounding factors, the results of a trend analysis suggest that the trend of an increasing probability of high GS occurrence with rising NHR holds statistical significance (OR: 1.47, 95% CI: 1.161.88, P = 0.0016) (Table 7).
Table 7 Multivariate Logistic Analysis to Determine Associations Between NHR Subgroup Levels and High Gensini Score (>80 Points)
Herein, subgroup analysis displayed that the tests for the interaction of age ( 60 vs > 60), sex (female vs male), systolic blood pressure (140vs>140), smoking, stroke, diabetes, hypertension, Gensini score>80, Killip Class 24, FPG levels (5.6 vs >5.6), HDL-C levels (1.1 vs >1.1) and LDL-C (2.51 vs 2.51) on the related effects of NHR and MACE were non-significant statistically (all P for interaction > 0.05) (Figure 4). The results showed that the various stratification factors in the model unaffected the correlation between NHR and MACE (Figure 4).
Figure 4 Stratified logistic regression analysis model to explore variables affecting the correlation between NHR and MACE. Above model adjusted for age ( 60 vs > 60), sex (female vs male), systolic blood pressure (140vs>140), smoking, stroke, diabetes, hypertension, Gensini score>80, Killip Class 24, FPG levels (5.6 vs >5.6), HDL-C levels (1.1 vs >1.1) and LDL-C (2.51 vs 2.51).
Abbreviations: NHR, Neutrophil to HDL-C ratio; MACE, major adverse cardiovascular events; FPG, fasting plasma glucose; HDL-C, High-density lipoprotein cholesterol; LDL-C, Low-density lipoprotein cholesterol.
Another subgroup analysis displayed that the tests for the interaction of age ( 60 vs > 60), sex (female vs male), systolic blood pressure (140vs >140), smoking, stroke, diabetes, hypertension, Killip Class 24, on the related effects of NHR and GS>80 were non-significant statistically (all P for interaction > 0.05) (Figure 5). The results showed that the various stratification factors in the model unaffected the correlation between NHR and GS>80 (Figure 5).
Figure 5 Stratified logistic regression analysis model to explore variables affecting the correlation between NHR and high Gensini score (GS>80). Above model adjusted for age ( 60 vs > 60), sex (female vs male), systolic blood pressure (140vs > 140), smoking, stroke, diabetes, hypertension, Killip Class 24.
Abbreviations: NHR, Neutrophil to HDL-C ratio; HDL-C, High-density lipoprotein cholesterol.
The ROC curve analysis was performed to evaluate the predictive ability of NHR, MHR, and LDL-C/HDL-C for in-hospital MACE in AMI patients after primary PCI. The results are as follows: NHR: The AUC for NHR was 0.681 with a 95% CI of (0.629, 0.732) (the specificity was 75.4%, the sensitivity was 52.7%, and the cut-off value was 9.17) (Table 8) (Figure 6A). MHR: The AUC for MHR was 0.672 with a 95% CI of (0.622, 0.722) (the specificity was 68.3%, the sensitivity was 60.1%, and the cut-off value was 0.64) (Table 8) (Figure 6A). LDL-C/HDL-C: The AUC for LDL-C/HDL-C was 0.618 with a 95% CI of (0.568, 0.668) (the specificity was 79.1%, the sensitivity was 45.0%, and the cut-off value was 2.46) (P < 0.05) (Table 8) (Figure 6A).
Table 8 ROC Curve of NHR, MHR and LDL-C/HDL-C Predicting for MACE After Percutaneous Coronary Intervention PCI in ST-Segment Elevation Acute Myocardial Infarction Patients
Figure 6 (A) ROC curve of NHR, MHR and LDL-C/HDL-C predicting the risk of MACE events during hospitalization in STEMI patients. (B) ROC curve of NHR, MHR and LDL-C/HDL-C predicting the risk of Gensini score>80.
Abbreviations: ROC curve, receiver operator characteristic curve; AUC, area under the curve; NHR, Neutrophil to HDL-C ratio; MHR, Monocyte to HDL-C ratio; HDL-C, High-density lipoprotein cholesterol; LDL-C, Low-density lipoprotein cholesterol; GS, Gensini score; MACE, major adverse cardiovascular events; STEMI, St-segment Elevation Myocardial Infarction.
Regarding the prediction of high GS, the ROC curve analysis of NHR, MHR, and LDL-C/HDL-C yielded the following results: NHR: The AUC for NHR was 0.649 with a 95% CI of (0.595, 0.703) (the specificity was 54.4%, the sensitivity was 70.1%, and the cut-off value was 7.24) (Table 9) (Figure 6B). MHR: The AUC for MHR was 0.587 with a 95% CI of (0.531, 0.643) (the specificity was 57.0%, the sensitivity was 60.6%, and the cut-off value was 0.58) (Table 9) (Figure 6B). LDL-C/HDL-C: The AUC for LDL-C/HDL-C was 0.620 with a 95% CI of (0.565, 0.676) (the specificity was 71.5%, the sensitivity was 47.9%, and the cut-off value was 2.57) (P < 0.05) (Table 9) (Figure 6B).
Table 9 ROC Curve of NHR, MHR and LDL-C/HDL-C Predicting for ST-Segment Elevation Acute Myocardial Infarction Patients with Gensini Score >80
These results indicated that NHR, MHR, and LDL-C/HDL-C have moderate predictive value for in-hospital MACE after primary PCI and NHR have moderate predictive value for high GS in STEMI patients.
The Spearman correlation analysis was conducted to examine the correlation between NHR, MHR, LDL-C/HDL-C, and GS. The results are as follows: NHR showed a significant correlation with GS (r=0.291, P<0.05) (Table 10) (Figure 7A). This indicates a moderate positive correlation between MHR and the severity of coronary artery lesions. MHR exhibited a lower correlation with GS compared to NHR (r=0.156, P<0.05) (Table 10) (Figure 7B). This suggests a weaker positive correlation between NHR and the severity of coronary artery lesions. LDL-C/HDL-C demonstrated a moderate positive correlation with GS (r=0.217, P<0.05) (Table 10) (Figure 7C). This implies that higher LDL-C/HDL-C are associated with increased severity of coronary artery lesions.
Table 10 Correlation of NHR, MHR and LDL-C/HDL-C with GS
Figure 7 (A) Correlation of NHR with Gensini score (Spearman correlation analysis). (B) Correlation of MHR with Gensini score (Spearman correlation analysis). (C) Correlation of LDL-C/HDL-C with Gensini score (Spearman correlation analysis).
Abbreviations: NHR, Neutrophil to HDL-C ratio; MHR, Monocyte to HDL-C ratio; HDL-C, High-density lipoprotein cholesterol; LDL-C, Low-density lipoprotein cholesterol.
These findings suggest that MHR, NHR, and LDL-C/HDL-C are correlated with the degree of stenosis reflected by the GS. Among these variables, MHR exhibited the strongest correlation, followed by LDL-C/HDL-C, while NHR had the lowest correlation.
The main finding of this study suggests that NHR has a better predictive value for the occurrence of MACE in hospitalized STEMI patients after PCI compared to MHR. Additionally, NHR demonstrates a potential predictive value for the degree of coronary artery stenosis as assessed by the GS. This study is unique in that it explores the predictive value of NHR in relation to MACE occurrence and coronary artery stenosis severity in hospitalized STEMI patients after PCI, an area that has not been extensively studied before.
The development of AMI is primarily attributed to vascular stenosis, myocardial ischemia, hypoxia, and myocardial injury resulting from coronary atherosclerosis.15 Inflammation and dyslipidemia play significant roles in the progression of atherosclerosis.36,16 However, relying solely on individual lipid levels or inflammatory markers may not provide sufficient accuracy in predicting the outcomes of AMI patients after PCI. Therefore, this study sought to investigate the association between NHR, MHR, and AMI, taking into consideration both inflammation and dyslipidemia aspects. By examining the combined inflammatory lipid markers, this study aimed to uncover potential relationships between these markers and the occurrence of MACEs as well as the severity of CAD in hospitalized AMI patients after PCI. The findings contribute to a deeper understanding of the complex interplay between inflammation, dyslipidemia, and adverse outcomes in AMI patients undergoing PCI.
STEMI primarily arises from thrombosis as a result of the rupture of coronary atherosclerotic plaques triggered by inflammation and abnormal lipid metabolism.5,17 Atherosclerosis is a complex process in which lipids interplay with immune-inflammatory cells. Research has demonstrated that inflammatory cell-derived substances possess the capability to instigate coagulation system activation, even in the absence of conventional risk factors, emphasizing the pivotal role of inflammatory system dysregulation in pathological thrombosis.18
During the progression of atherosclerosis, there is a substantial increase in the abundance of inflammatory immune cells such as monocytes and neutrophils. Monocytes have the ability to migrate into the vascular endothelium, where they transform into macrophages and express scavenger receptors crucial for the uptake of oxidized low-density lipoprotein cholesterol (OX-LDL-C). Upon the engulfment of oxidized LDL-C and other lipids, monocytes develop into foam cells, depositing within the intima of blood vessels to form atherosclerotic plaques, a significant contributor to the development of coronary atherosclerosis.
Despite being overlooked in cardiovascular research for a long time, the past decade has uncovered the significant regulatory role of neutrophils in cardiovascular inflammation. Neutrophils are implicated in all stages of atherosclerosis and have emerged as a crucial therapeutic target for the development of cardiovascular disease drugs.19 Studies have demonstrated a positive correlation between the extent of hypercholesterolemia-induced neutrophilia and the formation of early atherosclerotic lesions, which can influence atherosclerotic plaques and provoke thrombotic complications associated with atherosclerosis.20 Neutrophils release decondensed nucleosomes known as neutrophil extracellular traps (NETs), which induce platelet activation and initiate coagulation. Moreover, neutrophils secrete various pro-coagulant granzymes, collectively contributing to thrombosis formation and subsequent AMI.21
In AMI, neutrophils are recruited to the infarcted myocardium within the initial hours to initiate localized inflammation and tissue damage. The primary function of recruited neutrophils is to eliminate necrotic tissue from the site of myocardial injury.22 Unfortunately, neutrophils also exacerbate myocardial tissue destruction by releasing myeloperoxidase (MPO) and reactive oxygen species (ROS), which are associated with a poor prognosis in AMI patients.23 Nevertheless, neutrophils possess a dual role in cardiovascular inflammation, as they also play a reparative role.19 In addition, neutrophil-derived mediators regulate the functions of monocytes, macrophages, and dendritic cells, including recruitment, phagocytic capacity, and cytokine release.24,25 Previous investigations have demonstrated a high abundance of neutrophils in ruptured carotid plaques, suggesting a correlation between neutrophil count and the susceptibility to arterial plaque rupture.26 And the thrombosis secondary to plaque rupture represents the primary pathogenesis of STEMI.
In contrast to monocytes and neutrophils, HDL-C is recognized as a protective factor against atherosclerosis and cardiovascular risk.7,8 However, findings from Mendelian randomization studies suggest that HDL-C levels likely serve as a risk marker rather than a causative factor specific to cardiovascular events.27,28 HDL-C exerts its protective effects by facilitating reverse cholesterol transport, thereby reducing intravascular lipid deposition. Additionally, it attenuates atherosclerosis by inhibiting monocyte formation, decreasing monocyte recruitment to the arterial wall, and subsequently suppressing the inflammatory response.2933
NHR and MHR are novel indicators that reflect the interplay between inflammation and lipid metabolism. MHR represents the ratio of monocytes to HDL-C. Numerous studies have identified MHR as an independent risk factor for all-cause mortality and MACE in patients with STEMI after PCI.13,34,35 Wu TT et al demonstrated that MHR is also predictive of long-term outcomes in patients with AMI after PCI.36 Moreover, a study by E.T. Figueiredo et al indicated that MHR can provide prognostic value in acute coronary syndrome (ACS) patients to a certain extent.12 Similarly, MHR represents the ratio of neutrophils to HDL-C, is also a risk factor for MACE in patients after PCI.14 However, limited research has investigated the correlation between NHR and myocardial infarction, and there is currently a lack of studies examining the predictive value of NHR for both MACE occurrence and the extent of coronary artery stenosis in hospitalized AMI patients after PCI. Therefore, this research direction represents a relatively novel area of investigation.
In clinical practice, despite significant advancements in coronary intervention technology and PCI, the prognosis for patients with AMI remains challenging, with a high incidence of MACE. In this context, the use of NHR as a low-cost and readily available indicator holds promise in predicting the occurrence of MACE. Such prognostic information is invaluable for healthcare professionals, as it enables timely and appropriate interventions to prevent MACE and improve the overall prognosis of AMI patients.
Moreover, it is important to recognize that certain patients may not be suitable candidates for PCI due to factors such as hemodynamic instability, surgical refusal by family members, intervention time constraints, or limited hospital resources. In these situations, NHR can serve as an initial assessment tool for estimating the degree of coronary artery stenosis. This preliminary evaluation aids clinicians in determining appropriate symptomatic treatments for patients who cannot undergo immediate PCI.
This study aimed to compare the predictive value of NHR and MHR in predicting the occurrence of MACE in STEMI patients during hospitalization after PCI. Additionally, the study investigated their predictive value for evaluating the degree of coronary artery stenosis assessed by GS. The findings further support the superiority of NHR compared with MHR in predicting the occurrence of MACE in STEMI patients during hospitalization after PCI. Furthermore, the study suggests that NHR holds value in predicting the degree of coronary artery stenosis assessed by GS, whereas MHR does not appear to be a relevant predictor in this context. Therefore, compared to MHR, NHR may serve as a superior indicator for predicting the occurrence of MACE and the degree of coronary artery stenosis in STEMI patients during hospitalization undergoing PCI.
However, it is important to acknowledge several limitations in this study. Firstly, the retrospective nature and single-center design introduce potential biases that may limit the generalizability of the findings. Further studies conducted in multiple centers and with prospective designs are needed to validate the results. Secondly, the sample size in this study was relatively small and restricted to a specific region, which may affect the statistical power and external validity of the findings. Future studies with larger sample sizes and diverse populations are warranted. Thirdly, this study primarily focused on short-term prognosis during hospitalization, and the long-term prognostic value of NHR requires investigation through prospective studies. Furthermore, we have excluded patients who previously underwent PCI, or in cases where primary PCI failed to revascularize the culprit vessels. This decision was prompted by our consideration of the possibility that patients with a history of PCI may have experienced myocardial injury events. In most cases, individuals who have not successfully undergone vascular reconstruction exhibit myocardial injury levels surpassing those who have promptly undergone revascularization. As a result, the likelihood of MACE may experience an increase. Consequently, the correlation analysis involving NHR within these two distinct patient cohorts may yield disparate outcomes, and whether NHR has predictive value for prognosis and the degree of vascular stenosis in patients who primary PCI failed to revascularize the culprit vessels or previous undergo PCI requires further investigation.
The findings confirmed the significance of NHR and MHR in predicting MACE in this patient population, with NHR showing a higher predictive value. Furthermore, the study indicated that NHR holds value in predicting the degree of coronary artery stenosis assessed by GS, while MHR does not possess relevant predictive capability in this regard. These findings highlight the potential clinical utility of NHR as a predictive indicator in STEMI patients after PCI during hospitalization, both for MACE events and the degree of coronary artery stenosis.
NHR, neutrophil to high-density lipoprotein cholesterol ratio; MHR, monocyte to high-density lipoprotein cholesterol ratio; CAD, coronary artery disease; MACE, major adverse cardiovascular events; STEMI, ST-segment elevation acute myocardial infarction; PCI, percutaneous coronary intervention; CVD, cardiovascular diseases; US, the United States; AMI, acute myocardial infarction; HDL-C, high-density lipoprotein cholesterol; GS, Gensini score; CAG, coronary angiography; sCr, serum creatinine; BUN, blood urea nitrogen; UA, uric acid; ALB, albumin; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; FPG, fasting plasma glucose; LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; CI, confidence interval; OX-LDL-C, oxidized low-density lipoprotein cholesterol; NETs, neutrophil extracellular traps; MPO, myeloperoxidase; ROS, reactive oxygen species; ACS, acute coronary syndrome; ROC curves, Receiver operating characteristic curves; OR, the odds ratio.
The study protocol and informed consent procedures were approved by the Ethics Committee of the Third Affiliated Hospital of Anhui Medical University. All methods were performed following the Declaration of Helsinki. Informed written consent for publication without direct personal identification details (such as name and address) was obtained from all the participants.
The datasets used and/or analysed during the current study are available from the corresponding authors, Minmin Fu and Bingfeng Zhou, upon a reasonable request. The data are not publicly available due to their containing information that could compromise the privacy of patients.
The authors would like to extend their sincere thanks to YT H, HY Z and YZ for their contribution to data collection. We also extend our gratitude to JC G, MC, YH, BF Z and MM F for their contributions.
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
This research was funded by the Natural Science Project of Anhui Medical University in 2022 (2022xkj242).
The authors declare no conflicts of interest in this work.
1. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2023 Update: a Report From the American Heart Association. Circulation. 2023;147(8):e93e621. doi:10.1161/CIR.0000000000001123
2. bank Tw. Toward a Healthy and Harmonious Life in China: Stemming the Rising Tide of Non-Communicable Diseases. World Bank Report; 2014.
3. Libby P. Inflammation in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):20452051. doi:10.1161/atvbaha.108.179705
4. Schaftenaar F, Frodermann V, Kuiper J, Lutgens E. Atherosclerosis: the interplay between lipids and immune cells. Curr Opin Lipidol. 2016;27(3):209215. doi:10.1097/MOL.0000000000000302
5. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):34813488. doi:10.1161/CIRCULATIONAHA.105.537878
6. Pepine CJ, Nichols WW. The pathophysiology of chronic ischemic heart disease. Clin Cardiol Feb. 2007;30(2 Suppl 1):I49. doi:10.1002/clc.20048
7. Silbernagel G, Schottker B, Appelbaum S, et al. High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J. 2013;34(46):35633571. doi:10.1093/eurheartj/eht343
8. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):815. doi:10.1161/01.cir.79.1.8
9. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17(11):14101422. doi:10.1038/nm.2538
10. Matthias Nahrendorf FKS. Immunology. Neutrophil-macrophage communication in inflammation and atherosclerosis. Science. 2015;349(6245):237. doi:10.1126/science.aac7801
11. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol. 2010;7(2):7786. doi:10.1038/nrcardio.2009.228
12. Figueiredo ET, Miranda CH. Is the variation in monocyte to high-density lipoprotein cholesterol ratio a predictor of major cardiovascular events after acute coronary syndrome? Braz J Med Biol Res. 2023;55:e12410. doi:10.1590/1414-431X2022e12410
13. Villanueva DLE, Tiongson MD, Ramos JD, Llanes EJ. Monocyte to High-Density Lipoprotein Ratio (MHR) as a predictor of mortality and Major Adverse Cardiovascular Events (MACE) among ST Elevation Myocardial Infarction (STEMI) patients undergoing primary percutaneous coronary intervention: a meta-analysis. Lipids Health Dis. 2020;19(1):55. doi:10.1186/s12944-020-01242-6
14. Chen Y, Jiang D, Tao H, Ge P, Duan Q. Neutrophils to high-density lipoprotein cholesterol ratio as a new prognostic marker in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a retrospective study. BMC Cardiovasc Disord. 2022;22(1):434. doi:10.1186/s12872-022-02870-9
15. Boateng S, Sanborn T. Acute myocardial infarction. Dis Mon. 2013;59(3):8396. doi:10.1016/j.disamonth.2012.12.004
16. Stein R, Ferrari F, Scolari F. Genetics, Dyslipidemia, and Cardiovascular Disease: new Insights. Curr Cardiol Rep. 2019;21(8):67.
17. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114(12):18521866. doi:10.1161/CIRCRESAHA.114.302721
18. Swystun LL, Liaw PC. The role of leukocytes in thrombosis. Blood. 2016;128(6):753762. doi:10.1182/blood-2016-05-718114
19. Silvestre-Roig C, Braster Q, Ortega-Gomez A, Soehnlein O. Neutrophils as regulators of cardiovascular inflammation. Nat Rev Cardiol. 2020;17(6):327340. doi:10.1038/s41569-019-0326-7
20. Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation. 2010;122(18):18371845. doi:10.1161/CIRCULATIONAHA.110.961714
21. Pircher J, Czermak T, Ehrlich A, et al. Cathelicidins prime platelets to mediate arterial thrombosis and tissue inflammation. Nat Commun. 2018;9(1):1523. doi:10.1038/s41467-018-03925-2
22. Yonggang Ma AY, Merry L. Neutrophil roles in left ventricular remodeling following myocardial infarction. Fibrogenesis Tissue Repair. 2013;6:11. doi:10.1186/1755-1536-6-11
23. Daseke MJ, Valerio FM, Kalusche WJ, Ma Y, DeLeon-Pennell KY, Lindsey ML. Neutrophil proteome shifts over the myocardial infarction time continuum. Basic Res Cardiol. 2019;114(5):678.
24. Soehnlein O, Weber C, Lindbom L. Neutrophil granule proteins tune monocytic cell function. Trends Immunol. 2009;30(11):538546. doi:10.1016/j.it.2009.06.006
25. Soehnlein O, Zernecke A, Eriksson EE, et al. Neutrophil secretion products pave the way for inflammatory monocytes. Blood. 2008;112(4):14611471. doi:10.1182/blood-2008-02-139634
26. Ionita MG, van den Borne P, Catanzariti LM, et al. High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol. 2010;30(9):18421848. doi:10.1161/ATVBAHA.110.209296
27. Hassan M, Philip P. CANHEART: is HDL cholesterol a cardiovascular specific risk factor? Glob Cardiol Sci Pract. 2016;2016(4):e201634. doi:10.21542/gcsp.2016.34
28. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380(9841):572580. doi:10.1016/s0140-6736(12)60312-2
29. Rosenson RS, Brewer HB Jr, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13(1):4860. doi:10.1038/nrcardio.2015.124
More:
Comparison of the Predicting Value of NHR and MHR | JIR - Dove Medical Press
- ST-Segment Elevation Myocardial Infarction - verywell.com [Last Updated On: May 12th, 2018] [Originally Added On: May 12th, 2018]
- Myocardial infarction (Heart Attack) - Health Facts [Last Updated On: June 21st, 2018] [Originally Added On: June 21st, 2018]
- Heart Attack and Acute Coronary Syndrome - Lab Tests Online [Last Updated On: June 21st, 2018] [Originally Added On: June 21st, 2018]
- Myocardial Infarction - ECGpedia [Last Updated On: September 21st, 2018] [Originally Added On: September 21st, 2018]
- Myocardial Infarction Clinical Presentation: History ... [Last Updated On: September 25th, 2018] [Originally Added On: September 25th, 2018]
- Myocardial infarction diagnosis - Wikipedia [Last Updated On: September 25th, 2018] [Originally Added On: September 25th, 2018]
- Myocardial Infarction Treatment & Management: Approach ... [Last Updated On: October 9th, 2018] [Originally Added On: October 9th, 2018]
- Myocardial infarction - Simple English Wikipedia, the free ... [Last Updated On: October 18th, 2018] [Originally Added On: October 18th, 2018]
- ST-Segment Elevation Myocardial Infarction [Last Updated On: October 18th, 2018] [Originally Added On: October 18th, 2018]
- ECG localization of myocardial infarction / ischemia and ... [Last Updated On: October 18th, 2018] [Originally Added On: October 18th, 2018]
- Heart Attack (Myocardial Infarction) Symptoms | Cleveland Clinic [Last Updated On: November 15th, 2018] [Originally Added On: November 15th, 2018]
- Myocardial Infarction (Heart Attack) Ischemia Pathophysiology, ECG, Nursing, Signs, Symptoms Part 1 [Last Updated On: November 15th, 2018] [Originally Added On: November 15th, 2018]
- Myocardial Infarction (MI) NCLEX Questions [Last Updated On: November 30th, 2018] [Originally Added On: November 30th, 2018]
- Myocardial Infarction NCLEX Review (Part 1) [Last Updated On: December 3rd, 2018] [Originally Added On: December 3rd, 2018]
- Acute Myocardial Infarction, Myocardial infection. Patient [Last Updated On: December 4th, 2018] [Originally Added On: December 4th, 2018]
- Heart Attack | Myocardial Infarction | MedlinePlus [Last Updated On: December 16th, 2018] [Originally Added On: December 16th, 2018]
- Heart Attack (Myocardial Infarction) - medicinenet.com [Last Updated On: December 17th, 2018] [Originally Added On: December 17th, 2018]
- Myocardial infarction (acute): Early rule out using high ... [Last Updated On: December 20th, 2018] [Originally Added On: December 20th, 2018]
- Conditions We Treat: Myocardial Infarction | Johns Hopkins ... [Last Updated On: December 23rd, 2018] [Originally Added On: December 23rd, 2018]
- Myocardial Infarction - Heart Home Page [Last Updated On: December 25th, 2018] [Originally Added On: December 25th, 2018]
- Myocardial infarction: signs symptoms and treatment ... [Last Updated On: December 25th, 2018] [Originally Added On: December 25th, 2018]
- ECGs in Acute Myocardial Infarction - ACLS Medical Training [Last Updated On: December 25th, 2018] [Originally Added On: December 25th, 2018]
- Myocardial Infarction - Eccles Health Sciences Library [Last Updated On: December 27th, 2018] [Originally Added On: December 27th, 2018]
- Myocardial Infarction: Practice Essentials, Background ... [Last Updated On: December 27th, 2018] [Originally Added On: December 27th, 2018]
- Myocardial infarction - Wikipedia [Last Updated On: December 27th, 2018] [Originally Added On: December 27th, 2018]
- Nursing Care Plan for Myocardial Infarction | NRSNG [Last Updated On: December 29th, 2018] [Originally Added On: December 29th, 2018]
- Cardiovascular disease - Myocardial infarction | Britannica.com [Last Updated On: January 11th, 2019] [Originally Added On: January 11th, 2019]
- Heart Attack (Myocardial Infarction) - Cedars-Sinai [Last Updated On: January 11th, 2019] [Originally Added On: January 11th, 2019]
- Top 5 MI ECG Patterns You Must Know | LearntheHeart.com [Last Updated On: January 11th, 2019] [Originally Added On: January 11th, 2019]
- Anterior Myocardial Infarction LITFL ECG Library Diagnosis [Last Updated On: January 11th, 2019] [Originally Added On: January 11th, 2019]
- Electrocardiography in myocardial infarction - Wikipedia [Last Updated On: January 11th, 2019] [Originally Added On: January 11th, 2019]
- Myocardial Infarction Therapeutics Market, Share, Growth ... [Last Updated On: March 13th, 2019] [Originally Added On: March 13th, 2019]
- Heart Attack (Myocardial Infarction) - Drugs.com [Last Updated On: April 20th, 2019] [Originally Added On: April 20th, 2019]
- STEMI (ST Elevation Myocardial Infarction): diagnosis ... [Last Updated On: April 20th, 2019] [Originally Added On: April 20th, 2019]
- Heart attack - Symptoms and causes - Mayo Clinic [Last Updated On: April 20th, 2019] [Originally Added On: April 20th, 2019]
- Cardiovascular models including myocardial infarction ... [Last Updated On: April 27th, 2019] [Originally Added On: April 27th, 2019]
- Myocardial infarction - Osmosis Video Library [Last Updated On: May 1st, 2019] [Originally Added On: May 1st, 2019]
- Myocardial Infarction [Last Updated On: September 17th, 2019] [Originally Added On: September 17th, 2019]
- Creatinine Rises After RAS Inhibitor Initiation Tied to Worse Outcomes - Renal and Urology News [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Ventricular Tachycardia Treatment Market Growth in Technological Innovation, Competitive Landscape Mapping the Trends and Outlook - NewsVarsity [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- FDA Action Alert: Merck and Amarin - BioSpace [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Resverlogix Provides Update on BETonMACE Phase 3 Trial Toronto Stock Exchange:RVX - GlobeNewswire [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Marijuana Use Linked to Improved Acute-HF Hospital Survival - Medscape [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Population Health vs. Personalized Medicine: Lost in Translation? - American Council on Science and Health [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Bariatric Surgery Tied to Less MACE in Obesity, Diabetes - Medscape [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- A Novel Algorithm for Improving the Diagnostic Accuracy of Prehospital ST-Elevation Myocardial Infarction - DocWire News [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Shock and Awe: ARNI for Acute HF May Be Safely Started in ICU - Medscape [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Global Myocardial Infarction Treatment Market Will Reach USD 1726.3 million by end of 2022 - Market News Store [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Frequency and Factors Related to Not Receiving Acute Reperfusion Therapy in Patients with ST Elevation Myocardial Infarction; A Single Specialty... [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Research Offers 10-Year Forecast on Myocardial Infarction Treatment Market - Rapid News Network [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- University of Colorado study suggests Cannabis aids in surviving heart... - Communities Digital News [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- SRH part of regional system award recognizing care for heart attacks - Index-Journal [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- TherOx Announces Key SuperSaturated Oxygen Therapy Presentations at TCT 2019 - Yahoo Finance [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Incidence, Characteristics and Outcomes in Very Young Patients with ST Segment Elevation Myocardial Infarction - DocWire News [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Health Recovery After Acute MI Similar in Young Adults With and Without Diabetes - The Cardiology Advisor [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Rapid Diagnosis Protocol for Chest Pain Does Not Improve Outcomes - Diagnostic and Interventional Cardiology [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Diagnosis of Myocardial Infarction At Autopsy: AECVP Reappraisal in the Light of the Current Clinical Classification - DocWire News [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Global Myocardial Infarction Drug Market 2019 BioCardia, Inc., Biscayne Pharmaceuticals, Inc., Capricor Therapeutics, Inc., Cell - Market News Times [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Abiomed to Highlight Importance of Optimal PCI Treatment to Improve Outcomes for High-Risk Patients at TCT 2019 - Yahoo Finance [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- ENTRUST-AF PCI Supports Safety of Dual Therapy With Edoxaban - Medscape [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Preoperative opioid use leads to perioperative consequences in foot and ankle surgery - Healio [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- CV, General Safety of Long-Term PPI Use Examined - The Cardiology Advisor [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Effect of Delayed vs Immediate Interventions in Transient STEMI - The Cardiology Advisor [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Cardiorenal Disease Is the Most Common CVD Manifestation in Patients With T2D - Endocrinology Advisor [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- DAPA-HF Published: 'Stunning Consistent Benefit With Dapagliflozin' - Medscape [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Geomagnetic Disturbances and Cardiovascular Mortality Risk - On Health - BMC Blogs Network [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Reconsidering the Safety of Intravenous Thrombolysis for Ischemic Stroke After Recent Myocardial Infarction - Neurology Advisor [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- The Lowdown on Lipoprotein(a) - Medscape [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Protamine use found to significantly reduce reoperations for patients who undergo carotid endarterectomy - Vascular News [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Left Main Treated With PCI or CABG Have Similar Outcomes at Five Years - Diagnostic and Interventional Cardiology [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Sen. Sanders released from the hospital after heart attack - WXYZ [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- E-Selectin Gene Haplotypes are Associated with the Risk of Myocardial Infarction - DocWire News [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- BioVentrix Enrolls and Treats First Patient in REVIVE-HF European RCT for Ischemic Heart Failure Patients - P&T Community [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Quantitative Flow Ratio guided Residual Functional SYNTAX Score for Risk Assessment in Patients with ST-Segment Elevation Myocardial Infarction... [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Coronary Calcium Scan: The Role of Calcium Scoring in Preventing a First Myocardial Infarction - Consultant360 [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Sanders plans to 'change the nature' of campaign after heart attack - New York Post [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Early MI Linked to High Recurrent Events, Mortality - Medscape [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Sudden Cardiac Arrest and Ventricular Arrhythmias following first type I Myocardial Infarction in the Contemporary Era - DocWire News [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- E-Cigarette Use and Myocardial Infarction - Physician's Weekly [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Sen. Bernie Sanders had heart attack; chest pains diagnosed as myocardial infarction - KIRO Seattle [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]